Supplementary Figures 1-5, Tables 1-8 from Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Sharon E. Johnatty,Jonathan P. Tyrer,Siddhartha Kar,Jonathan Beesley,Yi Lu,Bo Gao,Peter A. Fasching,Alexander Hein,Arif B. Ekici,Matthias W. Beckmann,Diether Lambrechts,Els Van Nieuwenhuysen,Ignace Vergote,Sandrina Lambrechts,Mary Anne Rossing,Jennifer A. Doherty,Jenny Chang-Claude,Francesmary Modugno,Roberta B. Ness,Kirsten B. Moysich,Douglas A. Levine,Lambertus A. Kiemeney,Leon F.A.G. Massuger,Jacek Gronwald,Jan Lubiński,Anna Jakubowska,Cezary Cybulski,Louise Brinton,Jolanta Lissowska,Nicolas Wentzensen,Honglin Song,Valerie Rhenius,Ian Campbell,Diana Eccles,Weiva Sieh,Alice S. Whittemore,Valerie McGuire,Joseph H. Rothstein,Rebecca Sutphen,Hoda Anton-Culver,Argyrios Ziogas,Simon A. Gayther,Aleksandra Gentry-Maharaj,Usha Menon,Susan J. Ramus,Celeste L. Pearce,Malcolm C. Pike,Daniel O. Stram,Anna H. Wu,Jolanta Kupryjanczyk,Agnieszka Dansonka-Mieszkowska,Iwona K. Rzepecka,Beata Spiewankiewicz,Marc T. Goodman,Lynne R. Wilkens,Michael E. Carney,Pamela J. Thompson,Florian Heitz,Andreas du Bois,Ira Schwaab,Philipp Harter,Jacobus Pisterer,Peter Hillemanns,Beth Y. Karlan,Christine Walsh,Jenny Lester,Sandra Orsulic,Stacey J. Winham,Madalene Earp,Melissa C. Larson,Zachary C. Fogarty,Estrid Høgdall,Allan Jensen,Susanne Kruger Kjaer,Brooke L. Fridley,Julie M. Cunningham,Robert A. Vierkant,Joellen M. Schildkraut,Edwin S. Iversen,Kathryn L. Terry,Daniel W. Cramer,Elisa V. Bandera,Irene Orlow,Tanja Pejovic,Yukie Bean,Claus Høgdall,Lene Lundvall,Ian McNeish,James Paul,Karen Carty,Nadeem Siddiqui,Rosalind Glasspool,Thomas Sellers,Catherine Kennedy,Yoke-Eng Chiew,Andrew Berchuck,Stuart MacGregor,Paul D.P. Pharoah,Ellen L. Goode,Anna deFazio,Penelope M. Webb,Georgia Chenevix-Trench
DOI: https://doi.org/10.1158/1078-0432.22460870
2023-01-01
Abstract:Supplementary Figures 1-5, Tables 1-8. Supplementary Figure 1: Overview of the analytic approach. Supplementary Figure 2: QQ plots of SNPs with MAF ≥0.02 and imputation r2 ≥0.9 associated with Overall Survival in A. Supplementary Figure 3: ‘All OCAC’ histology-adjusted analysis. Supplementary Figure 4: Forest plots of promising SNPs. Supplementary Figure 5: KM-Plotter graphs of significant associations with outcome. Supplementary Table 1: All studies (OCAC & TCGA) eligible for analyses according to first-line chemotherapy. Supplementary Table 2: Description of individual OCAC studies included in the secondary 'all OCAC' analysis. Supplementary Table 3a: Overall Survival estimates for selected SNPs (MAF ≥0.02) comparing iCOGS imputed (r2 ≥0.3) and iPLEX genotyped samples. Supplementary Table 3b: Progression-free Survival estimates for selected SNPs (MAF ≥0.02) comparing iCOGS imputed (r2 ≥0.3) and iPLEX genotyped samples. Supplementary Table 4: SNPs with imputation r2 ≥0.9, EAF ≥0.02 and p ≤ 1E-05 for at least one of four outcomes analyzed in cases selected according to first-line chemotherapy. Supplementary Table 5: Meta-analysis of largest possible sample (TCGA, non-overlapping iCOGS and iplex genotyped) for selected promising SNPs analyzed in cases selected according to first-line chemotherapy. Supplementary Table 6: Significant association between protein-coding genes within 1Mb of promising SNPs and ovarian cancer outcomes. Supplementary Table 7: SNPs with imputation r-sq≥0.9 and p ≤ 1E-05 for Overall Survival in histology-adj 'all OCAC' analysis. Supplementary Table 8: iCOGS estimates for SNPs previously identified to be associated with response to chemotherapy as reported in the aNHGRI GWAS catalog.